Author

Laurent Beaugerie 1

1 Saint Antoine Hospital

BENEFIT OF INFLIXIMAB RE-INTRODUCTION AFTER SUCCESSIVE FAILURE OF INFLIXIMAB AND ADALIMUMAB IN INFLAMMATORY BOWEL DISEASES

Charlotte Gagniere, Laurent Beaugerie, Benjamin Pariente, Philippe Seksik, Aurelien Amiot, Vered Abitbol, Matthieu Allez, Jacques Cosnes, Harry Sokol

CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY

Catherine Reenaers, Stéphane Nancey, Guillaume Cadiot, Lucine Vuitton, Yoram Bouhnik, Pauline Riviere, Stéphanie Viennot, Vered Abitbol, Aurelien Amiot, Laurent Peyrin-Biroulet, Romain Altwegg, Florian Poullenot, Laurent Beaugerie, Guillaume Savoye, David Laharie, Laurence Picon, Mélanie Serrero, Mathias Vidon, Mathurin F

CARD9 IMPACTS COLITIS BY ALTERING GUT MICROBIOTA METABOLISM OF TRYPTOPHAN INTO ARYL HYDROCARBON RECEPTOR LIGANDS

Bruno Lamas, Mathias Lavie-Richard, Marie-Laure Michel, Valentin Leducq, Chantal Bridonneau, Grégory Da Costa, Laurent Beaugerie, Philippe Langella, Harry Sokol

Decision making based on risk factors and comorbidities

Laurent Beaugerie

EFFICACY AND SAFETY OF GOLIMUMAB IN CROHN’S DISEASE : A FRENCH NATIONAL RETROSPECTIVE STUDY

Chloé Martineau, Bernard Flourie, Pauline Wils, Thibaut Vaysse, Romain Altwegg, Anthony Buisson, Aurelien Amiot, Guillaume Pineton de Chambrun, Vered Abitbol, Mathurin Fumery, Xavier Hebuterne, Stéphanie Viennot, David Laharie, Laurent Beaugerie, Stéphane Nancey, Harry Sokol

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies

Vito Annese, Laurent Beaugerie, Laurence Egan, Livia Biancone, Claus Bolling, Christian Brandts, Daan Dierickx, Reinhard Dummer, Gionata Fiorino, Jean Marc Gornet, Peter D.R. Higgins, Konstantinos H. Katsanos, Loes Nissen, Gianluca Pellino, Gerhard Rogler, Franco Scaldaferri, Edyta Szymanska, Abraham (Rami) Eliakim

Evolution of endoscopic lesions in patients admitted for acute severe ulcerative colitis responding to infliximab or cyclosporine: sub-study from the CYSIF trial

David Laharie, Arnaud Bourreille, Julien Branche, Matthieu Allez, Yoram Bouhnik, Jerome Filippi, Frank Zerbib, Guillaume Savoye, Lucine Vuitton, Jacques Moreau, Aurelien Amiot, Laurent Beaugerie, Elena Ricart, Olivier Dewit, Antonio López San Román, Mathurin Fumery, Franck Carbonnel, Anthony Buisson, Benoit Coffin, Xavie

EXPOSURE TO COMBINATION THERAPY WITH THIOPURINES AND ANTI-TNF AGENTS IS ASSOCIATED WITH REDUCED INCIDENCE OF ACUTE ARTERIAL EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A NATIONWIDE FRENCH COHORT STUDY.

Julien Kirchgesner, Nynne Nyboe Andersen, Fabrice Carrat, Michaël Schwarzinger, Tine Jess, Laurent Beaugerie

FACTORS ASSOCIATED WITH DURABLE RESPONSE TO INFLIXIMAB 5 YEARS AND BEYOND: A MULTI CENTER INTERNATIONAL COHORT

Pascal Juillerat, Harry Sokol, Vijay Yajnik, Florian Froehlich, Laurent Beaugerie, Jacques Cosnes, Bernard Burnand, Andrew Macpherson, Joshua R. Korzenik

FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: A PILOT RANDOMIZED, SINGLE-BLIND, SHAM-CONTROLLED TRIAL

Harry Sokol, Cecilia Landman, Philippe Seksik, Laurence Berard, Melissa Montil, Isabelle Nion Larmurier, Anne Bourrier, Guillaume Legall, Valerie Lalande, Julien Kirchgesner, Anne Daguenel, Marine Cachanado, Alxandra Rousseau, Elodie Drouet, Xavier Dray, Philippe Marteau, Laurent Beaugerie, Tabassome Simon

Item 1 - 10 / 42
1
2 3 4 5